Aceite de oliva virgen extra beneficia la salud renal de los diabéticos

Aceite de oliva virgen extra beneficia la salud renal de los diabéticos

MÁLAGA, 10 Oct.

Investigation group in translational cardiovascular disease, belonging to the Biomedical Research Institute of Málaga and Nanomedicine Platform (Ibima Bionand Platform), has carried out a revolutionary study that could have a significant impact on the management of kidney diseases in Spain.

The researchers have discovered potential protective effects on the kidney in one of the polyphenols present in extra virgin olive oil (EVOO), 3',4'-dihydroxyphenylglycol (DHPG).

The study, which has been published in the journal Nutrients, is led by researchers from the Translational Research Group in Cardiovascular Disease, Dr. José Antonio González Correa and Dr. José Pedro de la Cruz Cortés.

In addition, professionals from the Department of Pharmacology at the University of Málaga, the Institute of Fat of the CSIC, the Gómez Ulla Central Defense Hospital, the Axarquía Hospital, and the Málaga-Guadalhorce Health District are participating.

The research focused on analyzing the impact of this polyphenolic compound on kidney lesions associated with type 1 diabetes, a condition that affects a large number of people in the country. The long-term complications of this disease, such as kidney diseases, represent a significant burden for patients and the healthcare system in Spain, they have stated in a press release.

The study, conducted on rodents, revealed promising results in which diabetic animals treated with the polyphenolic compound showed a reduction in oxidative and nitrosative stress, as well as an increase in the production of prostacyclin, an important biomarker for maintaining kidney function.

In addition, a decrease in protein excretion in the urine and improvements in the morphological parameters of the glomeruli, key indicators of kidney damage, were observed.

Dr. González Correa and Dr. De la Cruz Cortés, leaders of the Ibima Bionand research team, have commented on the results obtained that "our study provides promising evidence that the administration of DHPG to rodents with type 1 diabetes produces a nephroprotective effect. This is probably due to the combination of its antioxidant, antinitrosative, and prostacyclin production regulating effects."

"Furthermore, it is expected that the synergy of this product with other polyphenolic compounds will improve the renal protection induced by diabetes mellitus," they added.

These findings are an important step in the search for innovative solutions for the prevention and treatment of kidney diseases in Spain. Although further research is needed to fully understand the underlying mechanisms and confirm the results, the discovery of a compound in EVOO with renal protective potential opens up new avenues for research and development of more effective and specific therapies.